Loading data for JSPR — first visit, this takes a few seconds.

알림

Jasper Therapeutics Inc. (JSPR)

NasdaqCM: JSPR · 실시간 가격 · USD

0.70

+0.00 (0.00%)

종가 기준: Aug 31, 2026, 1:44 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

0.00% (1D)

매수호가	0.49
시가총액	22.36M
매출 (ttm)	n/a
순이익 (ttm)	-31.77M
	3.03
	-0.93
	n/a
	-0.26
P/B (ttm)	13.44
P/S (ttm)	n/a
실적 발표일	Nov 10, 2026

매도호가	0.86
거래량	265,031
평균 거래량 (20일)	1,548,551
시가	0.71
전일 종가	0.70
일중 범위	0.66 - 0.71
52주 범위	0.32 - 2.87
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

JSPR 소개

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with v...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jan 10, 2020

직원 수 22

상장 거래소 NasdaqCM

티커 JSPR

웹사이트 https://jaspertx.com

전체 기업 정보

재무 실적

2025년 Jasper Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -75.8M로, 6.36% 증가했습니다.

재무제표

어닝 서프라이즈

Jasper Therapeutics가 Aug 14, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -0.23 예상치 상회 0.32, 및 86.78% 전년 대비 성장.

다음 실적 발표

Jasper Therapeutics Inc.의 실적 발표 예정일은 Nov 10, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2주 전 · InvestorsHub

Jasper Therapeutics beats Q2 expectations but shares fall after results

Jasper Therapeutics Inc. (NASDAQ:JSPR) reported better-than-expected second-quarter 2026 results on Monday, although shares of the clinical-stage biotechnology company fell 4.

1개월 전 · BioPharma Dive

Jasper gets a lifeline in merger with immune drugmaker Kira

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.

2개월 전 · Zacks

Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement ...

4개월 전 · Insider Monkey

Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the 8 Most Oversold Penny Stocks to Buy Right Now. On April 1, 2026, Evercore ISI lowered the price target on Jasper Therapeutics, Inc. (NASDAQ:JSPR) ...

5개월 전 · Insider Monkey

Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the penny stocks with the potential to rise 1000 percent. UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a...

2 페이지 중 1

Jasper Therapeutics Inc. (JSPR)